Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04552990
Other study ID # 20-270
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 9, 2020
Est. completion date September 9, 2024

Study information

Verified date May 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 16
Est. completion date September 9, 2024
Est. primary completion date September 9, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subjects who meet all of the following criteria are eligible to participate in this study - Histologically-verified, previously untreated low-risk mixed superficial and nodular BCC(s) or nodular BCC(s) < 1 cm in diameter on scalp, extremities, or trunk. - = 18 years of age - Owner of a smartphone (Android or iPhone). Patients without a working smartphone will not be considered eligible for this study. - Being able to download application on their phone - Being able to take pictures of their treated BCC(s) (with or without assistance) - Female subjects of childbearing potential must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment. (Female subjects are considered of childbearing potential unless they have been hysterectomized or have undergone tubal ligation or have been post-menopausal for at least one year prior to the first visit) - Legally competent, able to give verbal and written informed consent - Subject in good general health and willing to participate comply with protocol requirements. - Superficial and nodular BCC(s) Exclusion Criteria: Subjects meeting any one of the following criteria are not eligible to participate in this study - High-risk BCC(s) (H area, >1 cm in M area, or >2 cm in L area) - BCC(s) subtype morpheaform - Diagnosed with gorlin syndrome - Receiving immunosuppressive medication - Subjects with a known allergy to ALA - Individuals with other interfering skin diseases in the area of treatment - Subjects with a tattoo in the treatment area which may interfere with or confound the evaluation of the study - Subjects with a history of keloids which is deemed clinically relevant in the opinion of the investigator - Lactating or pregnant women - Patient who are taking prescription pain medications or can not stop OTC pain medications.

Study Design


Intervention

Drug:
Jet injection of ALA
The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
Procedure:
Surgical excision
In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
Illumination
For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
Other:
Incubation
After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical evaluation of local skin responses on Day 0 Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 0 (PDT treatment #1) Day 1
Primary Clinical evaluation of local skin responses on Day 3 Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 3 Day 3
Primary Clinical evaluation of local skin responses on Day 14 Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 14 (PDT treatment #2) Day 14
Primary Clinical evaluation of local skin responses on Day 17 Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 17 Day 17
Primary Clinical evaluation of local skin responses 3 months post treatment Clinical evaluation of local skin responses on a 0-4 point scale will be performed 3 months post treatment 3 months after treatment
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT05608902 - Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Completed NCT05077033 - Intratumoral phIL12 GET Phase 1
Active, not recruiting NCT04928222 - Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) Phase 1/Phase 2
Recruiting NCT04929535 - Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment Phase 2
Completed NCT02662244 - Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma N/A
Completed NCT00959647 - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Phase 2
Completed NCT00793169 - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed NCT00586040 - Photochemical Tissue Bonding Phase 2
Completed NCT00473343 - Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma Phase 3
Active, not recruiting NCT06024629 - cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Not yet recruiting NCT05324202 - New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management N/A
Withdrawn NCT04099446 - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT01208831 - An East Asian Study of LDE225 Phase 1
Completed NCT01201915 - A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma Phase 2
Completed NCT01260987 - Fractional CO2 Laser Assisted Photodynamic Therapy Phase 2/Phase 3
Completed NCT01014819 - A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions N/A
Completed NCT00472043 - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Phase 3
Completed NCT00005660 - The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases N/A